X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1418) 1418
Book Review (311) 311
Newsletter (213) 213
Publication (133) 133
Book Chapter (11) 11
Newspaper Article (7) 7
Conference Proceeding (4) 4
Dissertation (4) 4
Reference (2) 2
Book / eBook (1) 1
Magazine Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
panitumumab (1580) 1580
index medicus (905) 905
cetuximab (888) 888
humans (839) 839
colorectal cancer (803) 803
oncology (758) 758
chemotherapy (552) 552
cancer (511) 511
colorectal neoplasms - drug therapy (483) 483
metastasis (386) 386
female (367) 367
male (352) 352
1st-line treatment (351) 351
colorectal neoplasms - genetics (350) 350
care and treatment (340) 340
research (336) 336
colorectal neoplasms - pathology (328) 328
mutation (327) 327
middle aged (316) 316
kras (305) 305
aged (295) 295
bevacizumab (294) 294
fluorouracil (290) 290
antibodies, monoclonal - therapeutic use (287) 287
antineoplastic agents - therapeutic use (258) 258
epidermal growth factor (256) 256
receptor, epidermal growth factor - antagonists & inhibitors (244) 244
ras proteins - genetics (241) 241
egfr (238) 238
adult (235) 235
antineoplastic combined chemotherapy protocols - therapeutic use (225) 225
leucovorin (223) 223
oxaliplatin (210) 210
growth-factor receptor (209) 209
proto-oncogene proteins p21 (203) 203
proto-oncogene proteins - genetics (202) 202
metastatic colorectal-cancer (196) 196
monoclonal antibodies (190) 190
treatment outcome (189) 189
metastatic colorectal cancer (187) 187
neoplasm metastasis (184) 184
open-label (180) 180
drug therapy (179) 179
phase-iii trial (179) 179
therapy (178) 178
genetic aspects (166) 166
analysis (163) 163
aged, 80 and over (162) 162
antibodies, monoclonal - administration & dosage (160) 160
tumors (157) 157
disease-free survival (152) 152
pharmacology & pharmacy (148) 148
prognosis (147) 147
antibodies, monoclonal, humanized (146) 146
cetuximab plus irinotecan (145) 145
health aspects (144) 144
proto-oncogene proteins b-raf - genetics (140) 140
irinotecan (139) 139
medicine & public health (139) 139
survival (139) 139
oncology, experimental (136) 136
braf (134) 134
immunotherapy (117) 117
antibodies, monoclonal - adverse effects (115) 115
clinical trials (112) 112
trial (109) 109
digestive system diseases (106) 106
epidermal growth factor receptor (105) 105
hematology, oncology and palliative medicine (105) 105
ras mutations (105) 105
animals (104) 104
cancer patients (104) 104
cancer therapies (104) 104
phase-iii (103) 103
antineoplastic agents (102) 102
colorectal neoplasms - mortality (101) 101
colorectal carcinoma (99) 99
expression (99) 99
patients (98) 98
antimitotic agents (94) 94
receptor, epidermal growth factor - metabolism (94) 94
camptothecin - analogs & derivatives (92) 92
efficacy (91) 91
monoclonal-antibody (91) 91
gene mutations (88) 88
antibodies, monoclonal - pharmacology (86) 86
antineoplastic agents - adverse effects (86) 86
antineoplastic agents - pharmacology (86) 86
metastases (84) 84
development and progression (83) 83
cell lung-cancer (81) 81
colon cancer (81) 81
colorectal neoplasms - metabolism (81) 81
erlotinib (81) 81
reports (81) 81
colon-cancer (80) 80
gefitinib (80) 80
surgery (80) 80
patient outcomes (79) 79
biomarkers, tumor - genetics (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1572) 1572
French (28) 28
German (19) 19
Spanish (14) 14
Japanese (9) 9
Czech (4) 4
Hungarian (3) 3
Korean (3) 3
Russian (3) 3
Chinese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2018, Volume 81, Issue 1, pp. 179 - 182
Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old metastatic colorectal cancer patient with... 
Renal insufficiency | Medicine & Public Health | Panitumumab | Colorectal cancer | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | THERAPY | SOLID TUMORS | ONCOLOGY | PHARMACOLOGY & PHARMACY | DYSFUNCTION | Antineoplastic Agents, Immunological - administration & dosage | Antineoplastic Agents, Immunological - pharmacokinetics | Glomerular Filtration Rate | Area Under Curve | Humans | Middle Aged | Half-Life | Male | Renal Insufficiency, Chronic - complications | Renal Insufficiency, Chronic - physiopathology | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - metabolism | Panitumumab - administration & dosage | Antineoplastic Agents, Immunological - adverse effects | Panitumumab - pharmacokinetics | Animals | Antineoplastic Agents, Immunological - therapeutic use | Colorectal Neoplasms - drug therapy | Panitumumab - therapeutic use | Colorectal Neoplasms - complications | Panitumumab - adverse effects | Antimitotic agents | Medical research | Safety and security measures | Chronic kidney failure | Pharmacy | Medicine, Experimental | Drugstores | Metastasis | Antineoplastic agents | Renal function | Approximation | Colorectal carcinoma | Radioactive half-life | Pharmacology | Dosage | Patients | Glomerular filtration rate | Metastases | Renal failure | Cancer | Kidney transplantation | Index Medicus | Original
Journal Article
Nature, ISSN 0028-0836, 06/2012, Volume 486, Issue 7404, pp. 532 - 536
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 10/2018, Volume 45, Issue 10, pp. 1435 - 1440
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 13, pp. 1704 - 1713
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 01/2015, Volume 372, Issue 3, pp. 291 - 292
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 02/2019, Volume 16, Issue 2, pp. 768 - 778
Our aim was to evaluate the effectiveness and normal tissue toxicity of radioimmunotherapy (RIT) of s.c. PANC-1 human pancreatic cancer (PnCa) xenografts in... 
Lu | radioimmunotherapy | panitumumab | EGFR | metal-chelating polymers
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2017, Volume 28, Issue 8, pp. 1862 - 1868
Background: Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on... 
First-line | RAS wild-type | Tumor sidedness | Panitumumab | Metastatic colorectal cancer | LOCATION | LEUCOVORIN | METAANALYSIS | MCRC | tumor sidedness | BEVACIZUMAB | PROXIMAL COLON | panitumumab | FLUOROURACIL | COLON-CANCER | CETUXIMAB | ONCOLOGY | FREE SURVIVAL PFS | first-line | metastatic colorectal cancer | Index Medicus | Original
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 06/2019, Volume 46, Issue 6, pp. e221 - e222
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 796 - 803
Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations because benefits of anti-EGFR therapies may depend... 
metastatic colorectal cancer | patient selection | digital PCR | panitumumab | PCR | FOLFIRI
Journal Article
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 03/2018, Volume 15, Issue 3, pp. 1150 - 1159
A metal-chelating polymer (MCP) with a polyglutamide (PGlu) backbone presenting on average 13 DOTA (tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelators... 
indium-111 | pancreatic cancer | radioimmunotherapy | metal-chelating polymers | lutetium-177 | panitumumab | imaging
Journal Article